Improving blood flow and insulin response in type 2 diabetes
Targeting ADAM17 activity for correction of vascular insulin resistance in type 2 diabetes
This study is looking at how a protein called ADAM17 affects blood flow and insulin response in people with type 2 diabetes, to see if blocking this protein can help improve blood sugar control and lower heart risks.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Missouri-Columbia NIH-funded |
| Lab location | 1 site (Columbia, United States) |
| Project ID | NIH-11043325 on NIH RePORTER |
What this research studies
This research investigates how targeting a specific protein, ADAM17, can improve blood flow and insulin response in patients with type 2 diabetes. The study aims to understand the mechanisms that lead to reduced blood flow and glucose uptake in these patients. By exploring the role of ADAM17 in insulin signaling, the researchers will test whether a compound that inhibits ADAM17 can enhance vascular insulin sensitivity. This could lead to new treatment strategies for managing blood sugar levels and reducing cardiovascular risks associated with diabetes.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults diagnosed with type 2 diabetes who experience issues with insulin response and blood flow.
Not a fit: Patients without type 2 diabetes or those with other underlying conditions affecting vascular health may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatments for type 2 diabetes that enhance blood flow and glucose control.
How similar studies have performed: Previous research has shown promising results in targeting similar pathways to improve insulin sensitivity, suggesting potential for success in this approach.
Where this research is happening
Columbia, United States
- University of Missouri-Columbia — Columbia, United States (Active)
Researchers
- Principal investigator: Martinez-Lemus, Luis a — University of Missouri-Columbia
- Study coordinator: Martinez-Lemus, Luis a
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.